Previous close | 2.3400 |
Open | 2.3400 |
Bid | 2.3000 x 50000 |
Ask | 2.3200 x 50000 |
Day's range | 2.3400 - 2.3400 |
52-week range | 1.4400 - 2.8000 |
Volume | |
Avg. volume | 1 |
Market cap | 886.535M |
Beta (5Y monthly) | 1.64 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8800 |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.00 |
Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while suppo
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the market. The Company’s management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on May 8, 2024, to discuss first quarter 2024 financial results and operational progress. A press release including the financial res
We feel now is a pretty good time to analyse Standard BioTools Inc.'s ( NASDAQ:LAB ) business as it appears the company...